Glucose-6-phosphate dehydrogenase (G6PD) is involved in the catalytic pentose phosphate pathway (PPP), which is closely related to energy metabolism. G6PD plays a crucial role in many types of cancer, but the specific molecular mechanisms of G6PD in cancer remain unclear. Therefore, we investigated the potential oncogenic role of G6PD in various tumors based on The Cancer Genome Atlas (TCGA), the cBioPortal datasets, the University of California Santa Cruz (UCSC) Xena browser, and the UALCAN-based online tool. G6PD was highly expressed in several cancer tissues (hepatocellular carcinoma, glioma, and breast cancer) compared with normal tissues and was significantly associated with poor prognosis of hepatocellular carcinoma, clear cell renal cell carcinoma, and breast cancer. Promoter methylation levels of G6PD were lower in Bladder Urothelial Carcinoma (BLCA) (P = 2.77e-02), breast invasive carcinoma (BRCA) (P = 1.62e-12), kidney renal clear cell carcinoma (KIRC) (P = 4.23e-02), kidney renal papillary cell carcinoma (KIRP) (P = 2.64e-03), liver hepatocellular carcinoma (LIHC) (P = 1.76e-02), stomach adenocarcinoma (STAD) (P = 3.50e-02), testicular germ cell tumors (TGCT) (P = 1.62e-12), higher in prostate adenocarcinoma (PRAD) (P = 1.81e-09), and uterine corpus endometrial carcinoma (UCEC) (P = 2.96e-04) compared with corresponding normal tissue samples. G6PD expression was positively correlated with the infiltration level of immune cells in most tumors, suggesting that G6PD may be involved in tumor immune infiltration. In addition, the functional mechanism of G6PD also involves 'Carbon metabolism', 'Glycolysis/Gluconeogenesis', 'Pentose phosphate pathway', and 'Central carbon pathway metabolism in cancer signaling pathway'. This pan-cancer study provides a relatively broad understanding of the oncogenic role of G6PD in various tumors and presents a theoretical basis for the development of G6PD inhibitors as therapeutic drugs for multiple cancers.

中文翻译：

---

人类肿瘤中 G6PD 致癌作用的泛癌分析。

6-磷酸葡萄糖脱氢酶（G6PD）参与催化磷酸戊糖途径（PPP），与能量代谢密切相关。G6PD在多种癌症中发挥着至关重要的作用，但G6PD在癌症中的具体分子机制仍不清楚。因此，我们基于癌症基因组图谱 (TCGA)、cBioPortal 数据集、加州大学圣克鲁斯分校 (UCSC) Xena 浏览器和基于 UALCAN 的在线工具研究了 G6PD 在各种肿瘤中的潜在致癌作用。与正常组织相比，G6PD在多种癌组织（肝细胞癌、胶质瘤和乳腺癌）中高表达，并且与肝细胞癌、透明细胞肾细胞癌和乳腺癌的不良预后显着相关。膀胱尿路上皮癌 (BLCA) (P = 2.77e-02)、乳腺浸润性癌 (BRCA) (P = 1.62e-12)、肾透明细胞癌 (KIRC) (P = 4.23) 中 G6PD 启动子甲基化水平较低e-02)、肾肾乳头状细胞癌 (KIRP) (P = 2.64e-03)、肝癌 (LIHC) (P = 1.76e-02)、胃腺癌 (STAD) (P = 3.50e-02) 、睾丸生殖细胞肿瘤 (TGCT) (P = 1.62e-12)、前列腺腺癌 (PRAD) (P = 1.81e-09) 和子宫体子宫内膜癌 (UCEC) (P = 2.96e-04) 相比较高与相应的正常组织样本。大多数肿瘤中G6PD表达与免疫细胞浸润水平呈正相关，提示G6PD可能参与肿瘤免疫浸润。此外，G6PD的功能机制还涉及“碳代谢”、“糖酵解/糖异生”、“磷酸戊糖途径”和“癌症信号传导途径中的中心碳途径代谢”。这项泛癌研究为G6PD在多种肿瘤中的致癌作用提供了相对广泛的认识，并为开发G6PD抑制剂作为多种癌症的治疗药物提供了理论基础。